Towards disease modification in osteoarthritis

Francesco Dell'Accio; Cosimo De Bari

doi:10.1016/j.joca.2023.05.002

Towards disease modification in osteoarthritis

Francesco Dell'Accio, Cosimo De Bari

University of London

Research output: Contribution to journal › Comment/debate › peer-review

1 Citation (Scopus)

Abstract

In December 2022, Gerwin et al published in Nature Medicine that the C-terminal portion of angiopoietin-like 3, called LNA043, has chondroprotective and cartilage-regenerative properties. Molecular data from an experimental medicine phase I study suggested potential efficacy in humans. Here, we respond to and complement a commentary from Vincent and Conaghan and discuss unresolved issues and the potential of this molecule as a disease-modifying osteoarthritis drug.

Original language	English
Pages (from-to)	1154-1155
Number of pages	2
Journal	Osteoarthritis and Cartilage
Volume	31
Issue number	9
Early online date	15 May 2023
DOIs	https://doi.org/10.1016/j.joca.2023.05.002
Publication status	Published - Sept 2023

Bibliographical note

F.D.A.’s research is supported by Versus Arthritis grants 22911 and FOREUM grant 1016807. C.D.B.’s research is supported by Versus Arthritis (grant numbers 20775, 21156, and 21800).

Access to Document

10.1016/j.joca.2023.05.002Licence: Unspecified

Cite this

@article{bf34ec4130884e8db405dc9bd158b84c,

title = "Towards disease modification in osteoarthritis",

abstract = "In December 2022, Gerwin et al published in Nature Medicine that the C-terminal portion of angiopoietin-like 3, called LNA043, has chondroprotective and cartilage-regenerative properties. Molecular data from an experimental medicine phase I study suggested potential efficacy in humans. Here, we respond to and complement a commentary from Vincent and Conaghan and discuss unresolved issues and the potential of this molecule as a disease-modifying osteoarthritis drug.",

author = "Francesco Dell'Accio and {De Bari}, Cosimo",

note = "F.D.A.{\textquoteright}s research is supported by Versus Arthritis grants 22911 and FOREUM grant 1016807. C.D.B.{\textquoteright}s research is supported by Versus Arthritis (grant numbers 20775, 21156, and 21800).",

year = "2023",

month = sep,

doi = "10.1016/j.joca.2023.05.002",

language = "English",

volume = "31",

pages = "1154--1155",

journal = "Osteoarthritis and Cartilage",

issn = "1063-4584",

publisher = "ELSEVIER APPL SCI PUBL LTD",

number = "9",

}

TY - JOUR

T1 - Towards disease modification in osteoarthritis

AU - Dell'Accio, Francesco

AU - De Bari, Cosimo

N1 - F.D.A.’s research is supported by Versus Arthritis grants 22911 and FOREUM grant 1016807. C.D.B.’s research is supported by Versus Arthritis (grant numbers 20775, 21156, and 21800).

PY - 2023/9

Y1 - 2023/9

N2 - In December 2022, Gerwin et al published in Nature Medicine that the C-terminal portion of angiopoietin-like 3, called LNA043, has chondroprotective and cartilage-regenerative properties. Molecular data from an experimental medicine phase I study suggested potential efficacy in humans. Here, we respond to and complement a commentary from Vincent and Conaghan and discuss unresolved issues and the potential of this molecule as a disease-modifying osteoarthritis drug.

AB - In December 2022, Gerwin et al published in Nature Medicine that the C-terminal portion of angiopoietin-like 3, called LNA043, has chondroprotective and cartilage-regenerative properties. Molecular data from an experimental medicine phase I study suggested potential efficacy in humans. Here, we respond to and complement a commentary from Vincent and Conaghan and discuss unresolved issues and the potential of this molecule as a disease-modifying osteoarthritis drug.

U2 - 10.1016/j.joca.2023.05.002

DO - 10.1016/j.joca.2023.05.002

M3 - Comment/debate

C2 - 37196976

SN - 1063-4584

VL - 31

SP - 1154

EP - 1155

JO - Osteoarthritis and Cartilage

JF - Osteoarthritis and Cartilage

IS - 9

ER -

Towards disease modification in osteoarthritis

Abstract

Bibliographical note

Access to Document

Fingerprint

Cite this